Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose CEOP plus filgrastim versus standard-dose CEOP for non-Hodgkin lymphoma
ACTRN12613000909729Phase 3Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 1994
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, epirubicin, vincristine, prednisolone and filgrastim in non-Hodgkin lymphoma (NHL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Overall survival. Started Mar 1994; status: completed.
02
Drugs
cyclophosphamideepirubicinvincristineprednisolonefilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ACTRN12613000909729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000909729.